COMPANY PROFILE

Bambusa Therapeutics

Explore full profile

A biotechnology company innovating transformative therapies for immunological and inflammatory disorders

Boston, United StatesFounded 2024Biotech & Life Sciences

Valuation $500M–1B Last recorded · 2025

Headcount <100 Current team size

Total funding $50–100M Disclosed equity funding

Unlock exact values

About Bambusa Therapeutics

Bambusa Therapeutics is a biotechnology company founded in 2024 and headquartered in Boston's Seaport area. The company develops bispecific antibodies for chronic and debilitating immunological and inflammatory (I&I) disorders, with a mission to advance the field of immunology through innovative approaches. Its pipeline targets substantial unmet medical needs: BBT001 is in Phase 2 for Type 2 inflammatory dermatological conditions including atopic dermatitis, chronic spontaneous urticaria and prurigo nodularis, while BBT002 targets Type 2 inflammation across asthma, chronic rhinosinusitis with nasal polyps, chronic obstructive pulmonary disease and related conditions. Preclinical candidates BBT003 and BBT004 address inflammatory bowel disease and autoantibody-driven autoimmune disease respectively. The company's antibody engineering platform incorporates half-life extension and high-concentration subcutaneous delivery. Led by co-founders Dr. Shanshan Xu and Helmut Jeggle, the team combines expertise in immunology, antibody engineering, clinical development and translational science.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2024
Headquarters: Boston, United States
Open positions: None listed
Dealroom signal: 0.0/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Biotech and Pharma, DT and LS
Business model: Manufacturing
Client focus: b2b
Links: Website

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

1 recorded event

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES A✓Equity / VC	Feb 2025	$90M	$360M	Redmile Group · RA Capital Management · Invus · Janus Henderson Investors	↗

Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

Bambusa Therapeutics website traffic

Latest recorded traffic for Bambusa Therapeutics is 5.4K monthly website visits, up 42.1% over the last three months.

Latest monthly visits5.4K 3-month web change+42.1%

Monthly website visitsFeb 2025–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
POPortocannaMedical cannabis processor creating Europe's largest symbiotic ecosystem with GMP facilities and diverse distribution	Santarém, Portugal	Operational	46	—	—
LPLX Bio PharmaceuticalsBiotechnology pharmaceutical company focused on developing antibody and bacteriophage therapies for unmet medical needs	Lisbon, Portugal	Operational
SBSparian BiosciencesClinical-stage biopharmaceuticals targeting CNS disorders with novel compounds and strategic collaborations	New York City, United States	Operational
LTLinseg TechAt Linseg Tech, spinoff of CEA, we have developed a patented breakthrough technology which allows a much easier access to super-resolution microscopy for all laboratories	Gif-sur-Yvette, France	Operational
NBNormax BiomedNormax focus for 2022 is rapid growth in mRNA Vaccine R&D and manufacturing for sustainable pandemic preparedness	Cork, Ireland	Operational
PTPhlox TherapeuticsRNA-based gene therapies for genetic heart diseases	Naarden, Netherlands	Operational
KPK PharmaInnovating medical treatments with iPS cell-based drug discovery and regenerative solutions	Tokyo, Japan	Operational
KTKismet TechnologiesSafe, new material technology (NanoRAD) that will help decrease how often people get sick by keeping surfaces pathogen free	Orlando, United States	Operational